Skip to Main content Skip to Navigation
Journal articles

PO-34 - Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor

Résumé : In clinical studies, thromboprophylaxis with low-molecular-weight heparins (LMWHs) has been demonstrated to reduce the risk of venous thromboembolism and to improve outcomes in cancer patients. Moreover, preclinical models have previously suggested that LMWHs may also offer additional benefits through direct antitumor properties. However, the optimal doses of LMWHs that may prevent both cancer-related thrombosis and tumor development are yet unknown.
Document type :
Journal articles
Complete list of metadatas

https://hal-amu.archives-ouvertes.fr/hal-01467510
Contributor : Françoise Dignat-George <>
Submitted on : Tuesday, February 14, 2017 - 3:05:24 PM
Last modification on : Tuesday, January 30, 2018 - 1:30:00 AM

Identifiers

  • HAL Id : hal-01467510, version 1
  • PUBMED : 27161722

Collections

Citation

Panicot-Dubois Laurence, Soraya Mezouar, Léa Plantureux, Lydie Crescence, C Frère, et al.. PO-34 - Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor. Thrombosis Research, Elsevier, 2016, pp.S189. ⟨hal-01467510⟩

Share

Metrics

Record views

100